研究动态
Articles below are published ahead of final publication in an issue. Please cite articles in the following format: authors, (year), title, journal, DOI.

产生 CCL19 的成纤维细胞促进三级淋巴结构形成,增强结直肠癌肝转移中的抗肿瘤 IgG 反应。

CCL19-producing fibroblasts promote tertiary lymphoid structure formation enhancing anti-tumor IgG response in colorectal cancer liver metastasis.

发表日期:2024 Aug 12
作者: Yifan Zhang, Guangjian Liu, Qianwen Zeng, Wenrui Wu, Kai Lei, Chuankai Zhang, Miaoling Tang, Yuting Zhang, Xiao Xiang, Li Tan, Rui Cui, Si Qin, Xinming Song, Changjun Yin, Zhihang Chen, Ming Kuang
来源: CANCER CELL

摘要:

三级淋巴结构(TLS)与肿瘤免疫力的增强有关。然而,它们在结直肠癌肝转移(CRLM)中的形成和功能仍不清楚。在这里,我们发现肿瘤内和肿瘤周围的成熟 TLS (TLS) 与 TLS 肿瘤相比改善的临床结果相关。使用单细胞RNA测序和空间增强分辨率组学测序(Stereo-seq),我们揭示了TLS肿瘤富含IgG浆细胞(PC),而TLS-肿瘤则以IgA浆细胞为特征。通过在体外生成 TLS 相关的 PC 衍生单克隆抗体,我们证明 TLS-PC 可以分泌肿瘤靶向抗体。作为概念验证,我们在结直肠癌人源化小鼠模型中展示了 TLS-PC-mAb6 抗体​​的抗肿瘤活性。我们鉴定出分泌 CCL19 的成纤维细胞谱系,可促进淋巴细胞转运至 TLS。 CCL19 治疗可促进小鼠 TLS 新生并防止肿瘤生长。我们的数据揭示了 CCL19 成纤维细胞在 TLS 形成中的核心作用,TLS 形成反过来又产生治疗性抗体来限制 CRLM。版权所有 © 2024 Elsevier Inc. 保留所有权利。
Tertiary lymphoid structures (TLSs) are associated with enhanced immunity in tumors. However, their formation and functions in colorectal cancer liver metastasis (CRLM) remain unclear. Here, we reveal that intra- and peri-tumor mature TLSs (TLS+) are associated with improved clinical outcomes than TLS- tumors. Using single-cell-RNA-sequencing and spatial-enhanced-resolution-omics-sequencing (Stereo-seq), we reveal that TLS+ tumors are enriched with IgG+ plasma cells (PCs), while TLS- tumors are characterized with IgA+ PCs. By generating TLS-associated PC-derived monoclonal antibodies in vitro, we show that TLS-PCs secrete tumor-targeting antibodies. As the proof-of-concept, we demonstrate the anti-tumor activities of TLS-PC-mAb6 antibody in humanized mouse model of colorectal cancer. We identify a fibroblast lineage secreting CCL19 that facilitates lymphocyte trafficking to TLSs. CCL19 treatment promotes TLS neogenesis and prevents tumor growth in mice. Our data uncover the central role of CCL19+ fibroblasts in TLS formation, which in turn generates therapeutic antibodies to restrict CRLM.Copyright © 2024 Elsevier Inc. All rights reserved.